EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analytical Validation of MyProstateScore 2.0—Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay

Tabea M Setera, Cameron J Seitz, Bradley S Moore, John R Kitchen, Spencer Heaton, Jingyi Cao, Jacob I Meyers

Diagnostics · 14.05.2026 · 16 (10) · 1486

DOI: 10.3390/diagnostics16101486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 14.05.2026. Verfasst von Tabea M Setera und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lynx Dx, Ann Arbor, MI 48108, USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Active surveillance (AS) is recommended for men with low-risk prostate cancer to minimize overtreatment while monitoring for disease progression. However, current surveillance strategies rely heavily on repeat biopsies, which are invasive and associated with morbidity. MyProstateScore 2.0—Active Surveillance (MPS2-AS) is a urine-based biomarker test developed to predict progression to Grade Group ≥ 2 (GG ≥ 2) and Grade Group ≥ 3 (GG ≥ 3) prostate cancers in men on AS. The objective of this study was to analytically validate the reproducibility and robustness of MPS2-AS analyte detection and risk score calculation across key laboratory variables.

Methods

Analytical precision was evaluated using pooled urine specimens processed using the MPS2-AS laboratory workflow. Eight pooled urine samples were tested in a within-laboratory design across five days, with two runs per day, and two replicates per run. Additional reproducibility studies assessed variability across three QuantStudio™ 12K Flex Real-Time PCR Systems and three OpenArray™ chip lots. Ten RNA biomarkers were quantified by RT-PCR and used to calculate the MPS2-AS GG1-2 and GG1-3 risk scores. Variance components were estimated using hierarchical ANOVA.

Results

The MPS2-AS analyte measurements demonstrated high precision across within-laboratory testing, with standard deviations ranging from 0.00 to 0.60 and coefficients of variation (%CV) from 0.00 to 4.01%. The reproducibility across qPCR instruments and OpenArray chip lots showed similar robustness, with analyte %CVs of ≤4.57% and ≤4.10%, respectively. These stable analyte measurements translated to reproducible model outputs, with %CV ≤ 10.69% for the GG1-2 risk score and ≤7.20% for the GG1-3 risk score across all tested conditions. No systematic bias was observed between runs, days, instruments, or reagent lots.

Conclusions

MPS2-AS demonstrates strong analytical precision and reproducibility for quantifying urinary biomarkers and generating GG1-2 and GG1-3 risk scores. These results support the reliability of MPS2-AS for clinical laboratory implementation and its use as a non-invasive tool to inform biopsy decisions in men with Grade Group 1 prostate cancer undergoing active surveillance.

Schlagwörter

Stichwörter der Autor:innen

MyProstateScore2.0—active surveillanceactive surveillanceanalytical validationprostate cancerurinary biomarkers

Autor:innen und Institutionen

  • Lynx Dx, Ann Arbor, MI 48108, USA.

Zitieren

APA

Setera, T. M., Seitz, C. J., Moore, B. S., Kitchen, J. R., Heaton, S., Cao, J., & Meyers, J. I. (2026). Analytical Validation of MyProstateScore 2.0—Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay. Diagnostics, 16(10), 1486. https://doi.org/10.3390/diagnostics16101486

Vancouver

Setera TM, Seitz CJ, Moore BS, Kitchen JR, Heaton S, Cao J, et al. Analytical Validation of MyProstateScore 2.0—Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay. Diagnostics. 2026;16(10):1486. doi:10.3390/diagnostics16101486

BibTeX
@article{Setera2026,
  author = {Setera, Tabea M and Seitz, Cameron J and Moore, Bradley S and Kitchen, John R and Heaton, Spencer and Cao, Jingyi and Meyers, Jacob I},
  title = {Analytical Validation of MyProstateScore 2.0—Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {10},
  pages = {1486},
  doi = {10.3390/diagnostics16101486}
}
Kostenlos starten →